CD19 and precursor B-cell acute lymphoblastic leukemia: A systematic review and meta-analysis by Elsallab et al. in 2023 showed that the overall response rate was 76% and the median overall survival of currently available autologous anti-CD19 CAR-T in relapsed/refractory B-ALL is 36.2 months (Table 1) [78].